Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): A mechanistic, non-randomised, repeat dose, open-label, response-adaptive study

BMJ Open

Volumn 5, Issue 12, 2015, Pages

  Truman, Lucy A ^a   Pekalski, Marcin L ^a   Kareclas, Paula ^b   Evangelou, Marina ^a,d   Walker, Neil M ^a   Howlett, James ^b,c   Mander, Adrian P ^c   Kennet, Jane ^a   Wicker, Linda S ^a   Bond, Simon ^b,c   Todd, John A ^a   Waldron Lynch, Frank ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDESLEUKIN; CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2;

ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; DOSE RESPONSE; DRUG SAFETY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; OPEN STUDY; PATIENT MONITORING; REGULATORY T LYMPHOCYTE; STUDY DESIGN; T LYMPHOCYTE; TREATMENT RESPONSE; ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84960414830     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-009799     Document Type: Article

References (38)

1. Daneman D. Type 1 diabetes. Lancet 2006;367:847-58.
2. Yang JH, Cutler AJ, Ferreira RC, et al. Natural variation in interleukin-2 sensitivity influences regulatory T-cell frequency and function in individuals with long-standing type 1 diabetes. Diabetes 2015;64:3891-902.
3. Oram RA, McDonald TJ, Shields BM, et al. Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors. Diabetes Care 2015;38:323-8.
4. The Diabetes Control and Complications Trial Research Group.. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
5. The Diabetes Control and Complications Trial Research Group. Hypoglycaemia in the Diabetes Control and Complications Trial. Diabetes 1997;46:271-86.
6. Steffes MW, Sibley S, Jackson M, et al. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26:832-6.
7. Kuhtreiber WM, Washer SL, Hsu E, et al. Low levels of C-peptide have clinical significance for established Type 1 diabetes. Diabet Med 2015;32:1346-53.
8. Todd JA. Etiology of type 1 diabetes. Immunity 2010;32:457-67.
9. Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010;10:490-500.
10. Todd JA, Walker NM, Cooper JD, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007;39:857-64.
11. Rubio-Cabezas O, Minton JA, Caswell R, et al. Clinical heterogeneity in patients with FOXP3 mutations presenting with permanent neonatal diabetes. Diabetes Care 2009;32:111-16.
12. Amy A. Caudy, Sreelatha T. Reddy, Talal Chatila, et al. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes J Allergy Clin Immunol 2007;119:482-7.
13. Garg G, Tyler JR, Yang JH, et al. Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. J Immunol 2012;188:4644-53.
14. Dendrou CA, Wicker LS. The IL-2/CD25 pathway determines susceptibility to T1D in humans and NOD mice. J Clin Immunol 2008;28:685-96.
15. Dendrou CA, Plagnol V, Fung E, et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet 2009;41:1011-15.
16. Burchill MA, Yang J, Vogtenhuber C, et al. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+regulatory T cells. J Immunology 2007;178:280-90.
17. Long SA, Cerosaletti K, Bollyky PL, et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4 (+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 2010;59:407-15.
18. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365: 2055-66.
19. Matsuoka K, Koreth J, Kim HT, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 2013;5:179ra43.
20. Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011;365:2067-77.
21. Virgin HW, Todd JA. Metagenomics and personalized medicine. Cell 2011;147:44-56.
22. Waldron-Lynch F, Kareclas P, Irons K, et al. Rationale and study design of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial. BMJ Open 2014;4:e005559.
23. Bond S, Mander A, Todd J, et al. Adaptive dose-finding designs to identify multiple doses that achieve multiple response targets. Trials 2013; 14:O78.
24. Hartemann A, Bensimon G, Payan CA, et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2013;1:295-305.
25. Rosenzwajg M, Churlaud G, Mallone R, et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J Autoimmun 2015;58:48-58.
26. Yu A, Snowhite I, Vendrame F, et al. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes 2015;64:2172-83.
27. Churlaud G, Jimenez V, Ruberte J, et al. Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infection, vaccination and cancer. Clin Immunol 2014;151:114-26.
28. Long SA, Buckner JH, Greenbaum CJ. IL-2 therapy in type 1 diabetes: 'Trials' and tribulations. Clin Immunol 2013;149:324-31.
29. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-96.
30. Abrams D, Lévy Y, Losso MH, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009;361:1548-59.
31. Long SA, Rieck M, Sanda S, et al. Rapamycin/IL-2 Combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes 2012;61:2340-8.
32. Heywood J, Evangelou M, Goymer D, et al. Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D). Trials 2015;16:86.
33. ADDRESS2. After Diabetes Diagnosis REsearch Support System (ADDRESS). 2014. http://www.address2.org/
34. DGAP. Diabetes: genes, autoimmunity and prevention. 2014. http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=5798
35. Poli A, Michel T, Thérésine M, et al. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 2009;126: 458-65.
36. Ito S, Bollard CM, Carlsten M, et al. Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. Mol Ther 2014;22:1388-95.
37. Sim GC, Martin-Orozco N, Jin L, et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest 2014;124:99-110.
38. Rosenzwajg M, Churlaud G, Hartemann A, et al. Interleukin-2 in the pathogenesis and therapy of type 1 diabetes. Curr Diab Rep 2014;14:553.